Brief: Antengene Corp - Acceptance Of NDA By Nmpa For Atg-010 (Selinexor) For Treatment Of Relapsed/Refractory Multiple Myeloma
28/01/2021 24:29
Jan 28 (Reuters) - Antengene Corp Ltd 6996.HK :
* ACCEPTANCE OF NDA BY NMPA FOR ATG-010 (SELINEXOR) FOR
TREATMENT
OF RELAPSED/REFRACTORY MULTIPLE MYELOMA
Source text for Eikon: ID:nHKS9dYv7f
Further company coverage: 6996.HK
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Antengene
See all newsBiotech firm Antengene's H1 revenue jumps on licensing deals
Brief: Antengene Corp Expects HY Profit Of RMB195 MLN-RMB238 MLN
Brief: Antengene Corp Receives Initial $60 Million Upfront Payment From UCB
Brief: Antengene Corp Intends To Repurchase Up To 67.92 Million Shares
Brief: Antengene Corp Enters Exclusive License Agreement With K2 Therapeutics For Atg-106